Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Albert A Rizvanov
-- 3755 2023-05-04 09:46:26 |
2 Reference format revised.
Lindsay Dong
 + 4 word(s) 3759 2023-05-05 10:41:38 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Issa, S.S.; Shaimardanova, A.A.; Solovyeva, V.; Rizvanov, A.A. Various Adeno-Associated Viruses Serotypes in Gene Therapy. Encyclopedia. Available online: https://encyclopedia.pub/entry/43741 (accessed on 14 May 2024).
Issa SS, Shaimardanova AA, Solovyeva V, Rizvanov AA. Various Adeno-Associated Viruses Serotypes in Gene Therapy. Encyclopedia. Available at: https://encyclopedia.pub/entry/43741. Accessed May 14, 2024.
Issa, Shaza Saleh, Alisa A. Shaimardanova, Valeriya Solovyeva, Albert A. Rizvanov. "Various Adeno-Associated Viruses Serotypes in Gene Therapy" Encyclopedia, https://encyclopedia.pub/entry/43741 (accessed May 14, 2024).
Issa, S.S., Shaimardanova, A.A., Solovyeva, V., & Rizvanov, A.A. (2023, May 04). Various Adeno-Associated Viruses Serotypes in Gene Therapy. In Encyclopedia. https://encyclopedia.pub/entry/43741
Issa, Shaza Saleh, et al. "Various Adeno-Associated Viruses Serotypes in Gene Therapy." Encyclopedia. Web. 04 May, 2023.
Various Adeno-Associated Viruses Serotypes in Gene Therapy
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cells12050785

Depending on their serotype, adeno-associated viruses (AAVs) can have specific tropism for specific organs and tissues of the body. There are different AAV serotypes that vary in many aspects. A variety of AAV features have made it an appealing viral vector candidate to be used in gene therapy applications. 

AAV serotype gene therapy Hereditary diseases rare diseases Adeno-Associated Viruses tissue tropism biopharmaceuticals orphan drugs biotechnology

1. Introduction

Adeno-associated viruses (AAVs) are small non-enveloped DNA viruses belonging to the Parvoviridae family, that were first isolated in 1965, as a contaminant in preparations of a simian adenovirus (Ad) [1][2]. The viruses were found incompetent to productively infect cells without a co-infection by a helper virus, usually an Ad or any type of herpesviruses, and thereby they were named as “adeno-associated”, and classified into the Dependovirus genus [3][4]. After being regarded as defective viruses for a long time due to their codependency, later studies on AAVs disproved this theory and showed that they rather launch a latent infection in the host cell, that could convert to productive infection under stress [4][5]. Although AAVs have a high seroprevalence in humans (it has been estimated that 50% to 96% of the human population is seropositive for the second serotype of AAV (AAV2) depending on age and ethnic group) [6][7][8], they, however, were not linked to any disease neither in humans, nor in any other species [4]. Different AAVs have not only been detected in primates isolates [9], but also from avian [10][11][12], caprine [13][14], bovine [15][16], and equine stocks [17].

Aside from AAV5 being the most divergent, all AAVs share a similar structure and properties [18]. AAVs are easy to manipulate, as their particles can maintain biological stability in extreme conditions of pH and temperature [19][20]. They share a genome of approximately 4.7 kb single-stranded DNA packed into an icosahedral, non-enveloped capsid with a diameter of 20–25 nm [2][21]. The AAV genome consists mainly of two viral genes: rep (replication) and cap (capsid), flanked by inverted terminal repeats (ITRs) [8][21]. As the ITRs have a palindromic nucleotide sequence, they create characteristic T-shaped hairpin structures, providing essential structural elements for viral genome replication and packaging [22]. ITRs also play a regulatory role in viral gene expression and host genome integration [6][23]. The open reading frame (ORF) of rep encodes several nonstructural proteins that are required for gene regulation, replication, transcription, and encapsidation [8][24][25], while the ORF of cap encodes three structural proteins: virion protein 1 (VP1), VP2, and VP3, with a molar ratio of 1:1:10 in AAV particles [6][26][27]. Distinct tissue tropism of different AAV serotypes results from variations in the processing of this cap ORF, leading to variant immune and transduction profiles [8][28].

2. AAV Serotypes and Tropism

2.1. AAV1

The exact origin of the first serotype of AAV (AAV1) is still unknown, as it was not initially isolated from tissues, but as a contaminant of Ad stocks [29][30], and its antibodies were found both in humans and non-human primates (NHPs) [31]. This serotype uses sialic acid as its primary cellular surface receptor [32], and AAV receptor (AAVR) as a coreceptor [33]. According to Rabinowitz J.E. et al., AAV1 does not bind heparin as it lacks R585 and R588, the amino acid residues required for such binding, and thereby it cannot be purified using heparin [29][34]. Zolotukhin S. et al., developed a protocol for AAV1 chromatographic purification by iodixanol gradient centrifugation and anion-exchange chromatography [35]. It can also be purified using mucin columns, as it can bind the sialic acid residues in mucin [36]. Moreover, recombinant AAV1 (rAAV1) was not found to contain any detectable post-translational modifications (PTMs), according to a systematic analysis conducted on ten AAV serotypes by Mary B. et al. [37], and it was the first viral vector to be approved for use in gene therapy [38].

2.2. AAV2

AAV2 is considered the most studied serotype among all AAVs [39]. It was first discovered in 1965 as a contaminant of simian Ad preparations [40]. Later, in 1998, its primary cellular receptor, heparan sulfate proteoglycan (HSPG), was identified by Summerford C. and Samulski R.J. [41], and the amino acid residues providing its affinity to HSPG were suggested, afterwards, as R585 and R588 [42]. Accordingly, rAAV2 can be purified using heparin column affinity chromatography [43]. Nevertheless, the binding of AAV2 to its primary receptor was found to be insufficient for cell entry, so several coreceptors were later identified for it [40], including the human fibroblast growth factor receptor 1 (FGFR1) [44], αVβ5 [45] and α5β1 integrins [46], hepatocyte growth factor receptor (HGFR) [47], laminin receptor (LR) [48], and CD9 [49]. The capsid of rAAV2 is reported to acquire multiple PTMs, including ubiquitination, phosphorylation, SUMOylation, and multiple-site-glycosylation [37].

2.3. AAV3

The third serotype of AAV (AAV3) was originally isolated from humans [30][39]. Similar to AAV2, this serotype uses HSPG, FGFR1, and LR receptors [48][50], along with the human HGFR (hHGFR) receptor [48]. Iodixanol gradient ultracentrifugation along with ion exchange chromatography have been used for AAV3 purification [51]. PTMs of rAAV3 capsid include acetylation, phosphorylation, and glycosylation [37]. Due to its inadequate transduction efficiency in vitro and in murine cell lines, AAV3 was mostly overlooked as a choice for gene therapy [52]. However, as it has been later found to use hHGFR as a coreceptor, it showed extremely efficient transduction of human liver cancer cells as well as human and NHP hepatocytes [52][53].

2.4. AAV4

The fourth serotype of AAV (AAV4) is considered one of the most antigenically distinct serotypes [54]. It has reportedly originated in NHPs [55], mainly in green African monkeys [56], as antibodies to its viral particles have been detected in their sera [57][58]. A study of the AAV4 structure showed that its capsid surface topology shares a significant similarity with that of human parvovirus B19 and Aleutian mink disease virus [54]. AAV4 uses a-2,3-O-linked sialic acid for cell binding and infection [59]; accordingly, mucin columns can be used for AAV4 purification, based on its ability to bind sialic acid residues in mucin [29][36]. In addition, as this serotype lacks heparin-binding activity, it cannot be purified using heparin column affinity chromatography like AAV2, however, ion-exchange chromatography procedures have been developed and proven a high purification efficiency [60].

2.5. AAV5

As it was first isolated in 1983 from male genital lesions, AAV5 became the only AAV serotype to be isolated directly from a human tissue [61]. This serotype is considered the most genetically divergent of all AAVs [2][62][63][64], with a variety of unique characteristics, such as the distinct size and function of its ITR regions [18], utilizing herpes simplex virus (HSV) as its helper virus for human infections [62], and using an atypical endocytic route as a pathway for viral entry [29]. Another distinctive feature of AAV5 is its ability to transduce cells that cannot be transduced with AAV2, an exclusive advantage for gene therapy uses [65][66][67]. AAV5 was also found to use sialic acid as its primary receptor [59][68][69], along with platelet-derived growth factor receptors (PDGFR) α and β as coreceptors [70][71].

2.6. AAV6

The classification of the sixth serotype of AAV (AAV6) is still a matter of controversy, as it presents high genomic similarity with both AAV1 and AAV2 serotypes, however, it has still been assigned its own serotype numbering [29][31]. AAV6 has a serological profile almost identical to that of AAV1, and shares its sequence of coding region with a homology percentage of 99%, along with multiple regions identical to those of AAV2 [72]. Accordingly, it was suggested to be a naturally occurring hybrid resulting from homologous RECOMation between AAV1 and AAV2 [31][39][72][73]. AAV6 was first isolated from a human Ad preparation [39][72][74], and similar to AAV1, was found to bind sialylated proteoglycans, mainly α2,3-/α2,6-linked sialic acid, as its primary receptor, as well as binding heparan sulfate [32][75][76]. As for its coreceptor, it binds epidermal growth factor receptor (EGFR) [77]. The only reported PTM of rAAV6 is acetylation of its capsid proteins [37].

2.7. AAV7

The seventh serotype of AAV (AAV7) was first isolated in 2002 from NHP tissues, specifically, from Rhesus macaque monkeys [31][78]. Its mechanisms of cell binding and cell entry are still unknown [40][79], but it is established that this serotype does not bind heparin, or any other glycan in general [80]. Capsid proteins of rAAV7 undergo multiple PTMs, including glycosylation, primarily, along with phosphorylation, SUMOylation, and acetylation [37]. A study by Calcedo R et al., investigated the epidemiology of AAV-neutralizing antibodies in the worldwide population, and found that the seroprevalence of AAV7 antibodies is relatively low in humans, an advantage of this serotype to be used in clinical applications [81]. Viral vectors based on AAV7 proved a high efficiency of transduction for skeletal muscle cells in murine models, similar to that achieved by AAV1, and higher than AAV2 [82]. This serotype also proved a strong tropism to hepatocytes in murine [83] and human [83] tissues. In CNS of NHPs, AAV7 viral vectors were found to achieve a robust transduction mainly in cortical and spinal tissues [84].

2.8. AAV8

Similar to AAV7, the eighth serotype of AAV (AAV8) was first isolated in 2002 from Rhesus macaque monkeys [31][78]. As a primary receptor, AAV8 binds LR, the same receptor used by AAV2 and AAV3 [39][48]. Various procedures for rapid and scalable purification of AAV8 have been developed since its discovery, including, for example, dual-ion-exchange chromatography [85][86], or iodixanol gradient centrifugation [87][88]. Phosphorylation, glycosylation, and acetylation are the three PTMs reported for rAAV8 capsid proteins [37]. AAV8 is best known for its strong tropism to liver cells, and accordingly, its transduction efficiency of hepatocytes, which is far stronger and faster than those of all other AAV serotypes in different models, including murine, canine, and NHP [83][89][90][91][92][93][94][95][96].

2.9. AAV9

The ninth serotype of AAV (AAV9) was first identified in a human isolate in 2004, and was named a new serotype as it had a serological profile distinct from the previously known AAVs, however, it was suggested to be closely related to clades containing AAV7 and AAV8 [78][97]. As a primary receptor, AAV9 uses terminal N-linked galactose [98][99], and it is also suggested to bind a putative integrin, along with LR as coreceptors [48][98]. Scalable simple purification protocols have been developed for AAV9 purification, including ion-exchange chromatography [20] and sucrose gradient centrifugation [100]. Capsid of rAAV9 has one of the highest totals of PTMs, including multiple ubiquitination, phosphorylation, SUMOylation, and glycosylation modifications, along with acetylation [37]. In most tissues, AAV9 seems to achieve cell transduction with efficiency superior to other AAVs [29][78]. For example, in a study aimed to investigate AAV1–9 distribution following systemic delivery in a murine model, AAV9 has shown rapid-onset, the best genome distribution, and the highest protein levels, in comparison with all other AAVs [83].

2.10. AAV10 and AAV11

The ninth and tenth serotypes of AAV (AAV10 and AAV11) were first found and described in 2004 in NHP isolates, namely from cynomolgus monkeys, with capsid proteins of great resemblance to AAV8 and AAV4, respectively [30][101], resulting in serological cross-reactivity with those two serotypes [102]. However, antisera against AAV10 and AAV11 were not found to have any cross-reactivity against those of AAV2, which recommended them as good viral vector candidates for gene therapy in individuals having antibodies against the latter [29]. It remains unknown what cellular receptors and coreceptors AAV10 and AAV11 use for cell binding and entry [33][74]; therefore, procedures describing their purification protocols are generally based on iodixanol gradient centrifugation [103]. Similar to AAV9, capsid of rAAV10 has one of the highest totals of PTMs, including mainly multiple glycosylation and phosphorylation modifications, along with ubiquitination, SUMOylation, and acetylation [37].

2.11. AAV12

The twelfth serotype of AAV (AAV12) was first isolated from a simian Ad stock, and then characterized as a novel serotype, as it exhibited distinctive biological and serological properties [104]. Although it was proven that AAV12 does not use heparan sulfate proteoglycans or sialic acids for attachment and cell entry, it remains unknown how exactly it binds target cells [101][104]. However, according to a study investigating components of a potential receptor complex for AAV12, mannose and mannosamine were suggested as components of such complex, as they inhibited AAV12 cell transduction [105].

2.12. AAV13

The thirteenth serotype of AAV (AAV13) is another simian Ad that appears to bind HSPG, although its primary cell receptor remains unknown [106][107][108]. It was also found to share structural similarity with AAV2 and AAV3, making it the closest related AAV to those two serotypes, with a capsid conserving all AAV capsids’ structural features [109], but there are only limited data on this serotype tropism and transduction efficiency [108].

2.13. Novel Hybrid AAV Vectors

In addition to the natural AAV serotypes described above, novel AAV vectors have been developed during the last two decades, and are still being developed [110]. Using different engineering strategies, novel hybrid vectors have been generated in order to enhance their transduction, modulate their immunogenicity, or limit their tropism to specific cells [111][112][113][114][115]. There has been different types of such engineered novel vectors, including mosaic, chimeric, and combinatorial vector libraries [29]. Mosaic vectors have multiple subunits of various serotypes in their capsid, chosen according to their properties of receptor binding and intracellular trafficking [29][116].

3. AAV as Viral Vectors for Gene Therapy Applications

3.1. AAV Viral Vectors for Gene Therapy of the CNS

AAV-mediated CNS gene therapy was first believed to predominantly target neurons, with lesser chance to affect other cells and tissues in the CNS [117], a fact that was later proven to be inaccurate in many studies [84][118][119][120]. For a variety of neurodevelopmental and neurodegenerative diseases, AAV-mediated gene therapy has been tested using different administration routes, including intraparenchymal, intrathecal, intracerebroventricular, and intracisternal injection, many of which have shown promising results [121].
Parkinson’s disease (PD) has been one of the most studied neurological disorders as a target for AAV-mediated gene therapy [117][122][123]. In a phase I clinical trial, Kaplitt et al., investigated an AAV-mediated gene therapy approach for advanced PD patients, where serotype 2 was used as a vector for unilateral subthalamic delivery of the glutamic acid decarboxylase (GAD) gene [124]. Providing a significant improvement in motor function scores up to 12 months after surgery, the approach was found to be safe and well-tolerated in patients. A similar double-blind, controlled, randomized clinical trial conducted later by LeWitt et al., investigated the same AAV2-GAD vector for bilateral subthalamic delivery in advanced PD patients, and showed similar results of safety and improvement of motor function [125]. Bartus et al., also tested the bilateral stereotactic delivery of AAV2-neurturin in PD patients of an open-label clinical trial, the initial obtained data of which supported the feasibility, safety, and good tolerance of the approach as a potential treatment for PD [126]. However, bilateral intra-striatal infusion of an AAV2 vector containing the aromatic L-amino acid decarboxylase (AADC) gene in moderately advanced PD patients led to an improvement in PD rating scales that was associated with a risk of intracranial hemorrhage in patients, along with headaches [127]. As for sustainable transgene expression, a clinical trial conducted by Mittermeyer G. et al., investigated the potentials of rAAV2 carrying the aromatic L-amino acid decarboxylase gene (rAAV2-AADC) [128]. In the trial, 10 patients with moderately advanced PD received bilateral infusions of recombinant vector into the putamin, showing good tolerance and a stable expression of transgene that lasted for the following 4 years, although higher vector doses were suggested for further studies. In children with AADC deficiency, the same delivery route for the same vector (rAAV2-AADC) was also assessed in an open-label phase I/II clinical trial [129]. The therapy was well-tolerated in general, providing evidence for potential improvement of motor function.

3.2. AAV Viral Vectors for Gene Therapy of Respiratory Diseases

For over 20 years, AAV vectors have been vastly investigated for gene therapeutics of respiratory diseases, both in preclinical experiments and human clinical trials [130][131]. However, a key limitation was that many AAV serotypes cannot efficiently transduce airway epithelial cells through the apical surface, suggesting molecular modifications of such serotypes to enhance their transduction efficiency [114]. Cystic fibrosis (CF) represents one of the most studied diseases as a target for AAV-mediated gene therapy [132]. In rabbits, AAV has proven to promote an efficient and stable gene transfer of the cystic fibrosis transmembrane conductance regulator (CFTR) gene into the airway epithelium, indicating, as a result, the vector potential to be used for gene therapy [133]. Subsequently, since 1998, clinical trials have started using recombinant AAV viral vectors to target different sites of the airway epithelium of CF patients, using variant administration routes [132][134][135]. The very first clinical trial to do so used the maxillary sinuses for delivery of recombinant AAV2 containing the CFTR gene (AAV2-CFTR) in ten CF patients, demonstrating a safe, successful transduction of targeted cells and a detected function restoration of the sinuses [135]. Soon after, a following phase II double-blind clinical trial tested unilateral administration of the same vector into the sinus for 23 CF patients, with an in-patient control, achieved by administering a placebo drug into the other sinus [136]. The approach again showed safety and good tolerance, although it did not confirm clinical effectiveness of the treatment. Aitken et al., also tested AAV2-CFTR in a phase I clinical trial for twelve mild CF patients using aerolization by nebulation for delivery, confirming the approaches safety, but failing to yield an effective clinical treatment [137]. Further trials on AAV2-CFTR with single or repeated dosing have yielded similar results of safety and good tolerance, providing little evidence of clinical treatment after intranasal and endobronchial delivery [138][139][140]. In order to optimize such therapeutic approaches and produce a functional CFTR in CF patients, further modifications of recombinant AAV vectors have since been developed [141][142]. Alpha-1 antitrypsin (α1AT or AAT) deficiency is another lung and liver disease that has been extensively studied as a target for AAV-mediated gene therapy both in vivo and in humans [131][143]. Reportedly, intravenous delivery of recombinant AAV vector carrying the human alpha-1 antitrypsin gene (AAV-hAAT) in the murine model resulted in potentially therapeutic serum levels of AAT [144][145]. Further research found that intrapleural delivery of rAAV2-hAAT or rAAV5-hAAT could achieve higher AAT levels both in lungs and serum compared to intramuscular delivery in C57BL/6 mice, with the rAAV5 showing 10-fold higher effectiveness than rAAV2 [146][147]. However, rAAV6/2-hAAT has been shown to transduce murine lung cells even more efficiently than rAAV5 both in vivo (in murine lung cells) and in vitro (in human airway epithelial cell culture) [148].

3.3. AAV Viral Vectors for Gene Therapy of Muscle Diseases

Having a large, body-distributed mass, and myofibers with a long half-life time makes muscles an attractive target for gene therapy, also considering the minimal invasiveness of the intramuscular delivery route [82][149]. Muscular dystrophies (MD) constitute a large group of muscle diseases that have been studied for a long time and proved to be a good target for AAV-mediated gene therapy [150]. For example, AAV1 carrying the follistatin gene, an antagonist of muscle growth negative regulator, has been shown to promote sustained improvement in muscle size and strength in NHPs following intramuscular administration [151]. There has also been many reports of both histopathological and functional sustained muscle restoration as a result of using AAV-mediated therapeutic approaches in animal models of Duchenne muscular dystrophy (DMD) [152][153], and Limb-Girdle muscular dystrophies (LGMD) [154][155][156][157][158].

3.4. AAV Viral Vectors for Gene Therapy of Cardiovascular and Blood Diseases

Cardiovascular diseases make another attractive target for gene therapy, being a leading cause of death globally with their high incidence and mortality rates [159][160]. As mentioned before, AAV serotypes 6, 8, and 9 have been shown to efficiently transduce cardiac cells in different animal models, and accordingly, they have been used for therapeutic purposes in different cardiovascular diseases [159][161][162][163][164].
In the search for an effective gene therapy platform for heat failure (HF), White J et al., published a study in 2011, in which they suggested a novel technique for AAV-mediated myocardial gene therapy using molecular cardiac surgery [159]. Using AAV6 in an ovine model, the suggested approach resulted in a global transgene expression, that was cardiac-tropic and substantially more robust and targeted, compared to that of intramuscular or intracoronary injection. Furthermore, a randomized phase I/II AAV1-based clinical trial for heart failure treatment was conducted in 2013, where the researchers used a sarcoplasmic reticulum calcium ATPase gene (SERCA2a), the product of which was suggested to play a key role in HF pathology [165]. As a result, adverse effects, including death, were found to be highest in the placebo group, and lowest in the high-dose group, with evidence of long-term transgene expression. However, in the low-dose and mid-dose groups, adverse effects were also found to be high but delayed.

3.5. AAV Viral Vectors for Gene Therapy of Liver Diseases

AAV-based gene therapy plays a significant role in liver diseases, as it is, in some cases, an alternative to the only effective therapy, which is liver transplantation [166]. In addition to the previously mentioned diseases affecting the liver, that have been targeted by AAV-base gene therapy, such as CF, AAT deficiency, and hemophilia, there are other liver diseases that have been targeted and continue to be, using AAV8, mainly.
Wilson’s disease (WD) is a rare autosomal recessive disease caused by mutations in the copper transporter gene, ATP7B, resulting in copper accumulation mainly in the liver, along with some other organs [167][168]. A recent in vivo study, conducted by Murillo et al., proved the efficacy of an AAV-based gene therapy for WD in a murine model of the disease [169].

3.6. AAV Viral Vectors for Gene Therapy of Endocrine Disorders

Being a major health issue for humans all around the world, with relatively high prevalence estimates, endocrine disorders have always been in the focus of research for therapeutic approaches and techniques [170][171]. Accordingly, rapid developments of diagnostic techniques, along with the better understanding of endocrine disorders’ pathophysiology and molecular bases, helped in developing different therapies, such as hormonal replacement therapies, for example [171][172]. However, as these approaches have mostly focused on improving the patient’s quality of life, reducing or reversing symptoms, rather than targeting the underlying defect, the resulting effect has not always been sufficient, which highlighted the need for gene therapy approaches, including AAV-based ones [172].
Type 1 diabetes mellitus (T1DM) is one of the endocrine autoimmune disorders that has been extensively studied as a target of gene therapy [173]. T1DM is characterized by self-destruction of insulin-secreting islet β cells, resulting from a wide variety of causative factors [174]. In non-obese diabetic (NOD) mice, administration of recombinant adeno-associated virus serotype 8 carrying DNA of mouse insulin promoter (dsAAV8-mIP) has been shown to prevent hyperglycemia in a dose-dependent manner [175]. High levels of mouse interleukin 10 (mIL-10) achieved following rAAV2-IL-10 intramuscular administration also proved to have a positive effect in NOD mice by decreasing autoimmunity, and thereby hyperglycemia [176]. Similarly, negative regulation of the immune response by programmed death ligand 1 (PDL1) was achieved in NOD mice following intraperitoneal delivery of AAV8-PDL1, which protected β cells [177].

3.7. AAV Viral Vectors for Gene Therapy of Cancer

Despite the variety of therapeutic approaches developed so far for cancer, including chemotherapy, radiotherapy, surgery, and different medications, cancer is still a huge health issue and a leading cause of death worldwide [178][179]. Several AAV-mediated cancer gene therapy approaches have been reported so far, including suicide gene, RNA-interference, and anti-angiogenesis gene therapies [178].
In AAV-mediated suicide gene therapy, an AAV-based system with herpes simplex virus type-1 thymidine kinase and ganciclovir (AAVtk/GCV) has been used. This system was found to exhibit a significant in vitro and in vivo tumor-suppressor efficacy in human head and neck cancer xenografts in a murine model [180][181][182], and murine models of bile duct cancer [183] and bladder carcinoma [184].

References

  1. Atchison, R.W.; Casto, B.C.; Hammon, W.M. Adenovirus-associated defective virus particles. Science 1965, 149, 754–756.
  2. Mezzina, M.; Merten, O.W. Adeno-associated viruses. Methods Mol. Biol. 2011, 737, 211–234.
  3. Hoggan, M.D.; Blacklow, N.R.; Rowe, W.P. Studies of small DNA viruses found in various adenovirus preparations: Physical, biological, and immunological characteristics. Proc. Natl. Acad. Sci. USA 1966, 55, 1467–1474.
  4. Berns, K.I.; Giraud, C. Biology of adeno-associated virus. Curr. Top. Microbiol. Immunol. 1996, 218, 1–23.
  5. Yalkinoglu, A.O.; Heilbronn, R.; Bürkle, A.; Schlehofer, J.R.; zur Hausen, H. DNA amplification of adeno-associated virus as a response to cellular genotoxic stress. Cancer Res. 1988, 48, 3123–3129.
  6. Gonçalves, M.A.F.V. Adeno-associated virus: From defective virus to effective vector. Virol. J. 2005, 2, 43.
  7. Erles, K.; Sebökovà, P.; Schlehofer, J.R. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J. Med. Virol. 1999, 59, 406–411.
  8. Büning, H.; Perabo, L.; Coutelle, O.; Quadt-Humme, S.; Hallek, M. Recent developments in adeno-associated virus vector technology. J. Gene Med. 2008, 10, 717–733.
  9. Tijssen, P. Handbook of Parvoviruses Vol. I and Vol. II Continued; CRC Press, Inc.: Boca Raton, FL, USA, 1990.
  10. Grimes, T.; King, D.; Fletcher, O. Serologic and pathogenicity studies of avian adenovirus isolated from chickens with inclusion body hepatitis. Avian Dis. 1978, 22, 177–180.
  11. Alvarado, I.; Villegas, P.; El-Attrache, J.; Jensen, E.; Rosales, G.; Perozo, F.; Purvis, L.J. Genetic characterization, pathogenicity, and protection studies with an avian adenovirus isolate associated with inclusion body hepatitis. Avian Dis. 2007, 51, 27–32.
  12. Bossis, I.; Chiorini, J.A. Cloning of an avian adeno-associated virus (AAAV) and generation of recombinant AAAV particles. J. Virol. 2003, 77, 6799–6810.
  13. Arbetman, A.E.; Lochrie, M.; Zhou, S.; Wellman, J.; Scallan, C.; Doroudchi, M.M.; Randlev, B.; Patarroyo-White, S.; Liu, T.; Smith, P. Novel caprine adeno-associated virus (AAV) capsid (AAV-Go. 1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties. J. Virol. 2005, 79, 15238–15245.
  14. Olson, E.J.; Haskell, S.R.; Frank, R.K.; Lehmkuhl, H.D.; Hobbs, L.A.; Warg, J.V.; Landgraf, J.G.; Wünschmann, A. Isolation of an adenovirus and an adeno-associated virus from goat kids with enteritis. J. Vet.-Diagn. Investig. 2004, 16, 461–464.
  15. Schmidt, M.; Katano, H.; Bossis, I.; Chiorini, J.A. Cloning and characterization of a bovine adeno-associated virus. J. Virol. 2004, 78, 6509–6516.
  16. Coria, M.; Lehmkuhl, H. Isolation and identification of a bovine adenovirus type 3 with an adenovirus-associated virus. J. Vet.-Diagn. Investig. 1978, 39, 1904–1906.
  17. Dutta, S.K. Isolation and characterization of an adenovirus and isolation of its adenovirus-associated virus in cell culture from foals with respiratory tract disease. Am. J. Vet. Res. 1975, 36, 247–250.
  18. Qiu, J.; Pintel, D.J. Alternative polyadenylation of adeno-associated virus type 5 RNA within an internal intron is governed by the distance between the promoter and the intron and is inhibited by U1 small nuclear RNP binding to the intervening donor. J. Biol. Chem. 2004, 279, 14889–14898.
  19. Merten, O.W.; Gény-Fiamma, C.; Douar, A.M. Current issues in adeno-associated viral vector production. Gene Ther. 2005, 12 (Suppl. S1), S51–S61.
  20. Potter, M.; Lins, B.; Mietzsch, M.; Heilbronn, R.; Van Vliet, K.; Chipman, P.; Agbandje-McKenna, M.; Cleaver, B.D.; Clément, N.; Byrne, B.J.; et al. A simplified purification protocol for recombinant adeno-associated virus vectors. Mol. Ther. Methods Clin. Dev. 2014, 1, 14034.
  21. Carter, P.J.; Samulski, R.J. Adeno-associated viral vectors as gene delivery vehicles. Int. J. Mol. Med. 2000, 6, 17–27.
  22. Cataldi, M.P.; McCarty, D.M. Hairpin-end conformation of adeno-associated virus genome determines interactions with DNA-repair pathways. Gene Ther. 2013, 20, 686–693.
  23. Michelfelder, S.; Trepel, M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv. Genet. 2009, 67, 29–60.
  24. Dubielzig, R.; King, J.A.; Weger, S.; Kern, A.; Kleinschmidt, J.A. Adeno-associated virus type 2 protein interactions: Formation of pre-encapsidation complexes. J. Virol. 1999, 73, 8989–8998.
  25. Kyöstiö, S.R.; Owens, R.A.; Weitzman, M.D.; Antoni, B.A.; Chejanovsky, N.; Carter, B.J. Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels. J. Virol. 1994, 68, 2947–2957.
  26. Galibert, L.; Hyvönen, A.; Eriksson, R.A.E.; Mattola, S.; Aho, V.; Salminen, S.; Albers, J.D.; Peltola, S.K.; Weman, S.; Nieminen, T.; et al. Functional roles of the membrane-associated AAV protein MAAP. Sci. Rep. 2021, 11, 21698.
  27. Kronenberg, S.; Kleinschmidt, J.A.; Böttcher, B. Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids. EMBO Rep. 2001, 2, 997–1002.
  28. Rabinowitz, J.E.; Samulski, R.J. Building a better vector: The manipulation of AAV virions. Virology 2000, 278, 301–308.
  29. Wu, Z.; Asokan, A.; Samulski, R.J. Adeno-associated virus serotypes: Vector toolkit for human gene therapy. Mol. Ther. J. Am. Soc. Gene Ther. 2006, 14, 316–327.
  30. Mori, S.; Wang, L.; Takeuchi, T.; Kanda, T. Two novel adeno-associated viruses from cynomolgus monkey: Pseudotyping characterization of capsid protein. Virology 2004, 330, 375–383.
  31. Gao, G.P.; Alvira, M.R.; Wang, L.; Calcedo, R.; Johnston, J.; Wilson, J.M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA 2002, 99, 11854–11859.
  32. Wu, Z.; Miller, E.; Agbandje-McKenna, M.; Samulski, R.J. Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J. Virol. 2006, 80, 9093–9103.
  33. Li, C.; Samulski, R.J. Engineering adeno-associated virus vectors for gene therapy. Nat. Rev. Genet. 2020, 21, 255–272.
  34. Rabinowitz, J.E.; Rolling, F.; Li, C.; Conrath, H.; Xiao, W.; Xiao, X.; Samulski, R.J. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 2002, 76, 791–801.
  35. Zolotukhin, S.; Potter, M.; Zolotukhin, I.; Sakai, Y.; Loiler, S.; Fraites, T.J., Jr.; Chiodo, V.A.; Phillipsberg, T.; Muzyczka, N.; Hauswirth, W.W.; et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002, 28, 158–167.
  36. Robert, M.A.; Chahal, P.S.; Audy, A.; Kamen, A.; Gilbert, R.; Gaillet, B. Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms. Biotechnol. J. 2017, 12, 1600193.
  37. Mary, B.; Maurya, S.; Arumugam, S.; Kumar, V.; Jayandharan, G.R. Post-translational modifications in capsid proteins of recombinant adeno-associated virus (AAV) 1-rh10 serotypes. FEBS J. 2019, 286, 4964–4981.
  38. Huang, L.-Y.; Patel, A.; Ng, R.; Miller, E.B.; Halder, S.; McKenna, R.; Asokan, A.; Agbandje-McKenna, M.; Banks, L. Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site. J. Virol. 2016, 90, 5219–5230.
  39. Lisowski, L.; Tay, S.S.; Alexander, I.E. Adeno-associated virus serotypes for gene therapeutics. Curr. Opin. Pharmacol. 2015, 24, 59–67.
  40. Srivastava, A. In vivo tissue-tropism of adeno-associated viral vectors. Curr. Opin. Virol. 2016, 21, 75–80.
  41. Summerford, C.; Samulski, R.J. Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions. J. Virol. 1998, 72, 1438–1445.
  42. Opie, S.R.; Warrington, K.H., Jr.; Agbandje-McKenna, M.; Zolotukhin, S.; Muzyczka, N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 2003, 77, 6995–7006.
  43. Auricchio, A.; Sena-Esteves, M.; Gao, G. Purification of Recombinant Adeno-Associated Virus 2 (rAAV2) by Heparin Column Affinity Chromatography. Cold Spring Harb. Protoc. 2020, 2020, 095620.
  44. Qing, K.; Mah, C.; Hansen, J.; Zhou, S.; Dwarki, V.; Srivastava, A.J. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 1999, 5, 71–77.
  45. Summerford, C.; Bartlett, J.S.; Samulski, R.J.J. αVβ5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nat. Med. 1999, 5, 78–82.
  46. Asokan, A.; Hamra, J.B.; Govindasamy, L.; Agbandje-McKenna, M.; Samulski, R.J.J. Adeno-associated virus type 2 contains an integrin α5β1 binding domain essential for viral cell entry. J. Virol. 2006, 80, 8961–8969.
  47. Kashiwakura, Y.; Tamayose, K.; Iwabuchi, K.; Hirai, Y.; Shimada, T.; Matsumoto, K.; Nakamura, T.; Watanabe, M.; Oshimi, K.; Daida, H.J. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J. Virol. 2005, 79, 609–614.
  48. Akache, B.; Grimm, D.; Pandey, K.; Yant, S.R.; Xu, H.; Kay, M.A.J. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 2006, 80, 9831–9836.
  49. Kurzeder, C.; Koppold, B.; Sauer, G.; Pabst, S.; Kreienberg, R.; Deissler, H.J. CD9 promotes adeno-associated virus type 2 infection of mammary carcinoma cells with low cell surface expression of heparan sulphate proteoglycans. Int. J. Mol. Med. 2007, 19, 325–333.
  50. Blackburn, S.D.; Steadman, R.A.; Johnson, F.B. Attachment of adeno-associated virus type 3H to fibroblast growth factor receptor 1. Arch. Virol. 2006, 151, 617–623.
  51. Ling, C.; Wang, Y.; Zhang, Y.; Ejjigani, A.; Yin, Z.; Lu, Y.; Wang, L.; Wang, M.; Li, J.; Hu, Z.; et al. Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 2014, 25, 1023–1034.
  52. Ling, C.; Yin, Z.; Li, J.; Zhang, D.; Aslanidi, G.; Srivastava, A. Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors. Mol. Ther. Methods Clin. Dev. 2016, 3, 16029.
  53. Handa, A.; Muramatsu, S.I.; Qiu, J.; Mizukami, H.; Brown, K.E. Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. J. Gen. Virol. 2000, 81, 2077–2084.
  54. Padron, E.; Bowman, V.; Kaludov, N.; Govindasamy, L.; Levy, H.; Nick, P.; McKenna, R.; Muzyczka, N.; Chiorini, J.A.; Baker, T.S.; et al. Structure of adeno-associated virus type 4. J. Virol. 2005, 79, 5047–5058.
  55. Parks, W.P.; Boucher, D.W.; Melnick, J.L.; Taber, L.H.; Yow, M.D. Seroepidemiological and ecological studies of the adenovirus-associated satellite viruses. Infect. Immun. 1970, 2, 716–722.
  56. Blacklow, N.R.; Hoggan, M.D.; Rowe, W.P. Serologic evidence for human infection with adenovirus-associated viruses. J. Natl. Cancer Inst. 1968, 40, 319–327.
  57. Dreizin, R.S.; Zhuravel, T.F.; Tarasova, A.B.; Sobolev, S.G.; Kozlov, V.G. Experimental infection of green monkeys with adenoassociated virus. Vopr. Virusol. 1981, 1, 82–89.
  58. Chiorini, J.A.; Yang, L.; Liu, Y.; Safer, B.; Kotin, R.M. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 1997, 71, 6823–6833.
  59. Kaludov, N.; Brown, K.E.; Walters, R.W.; Zabner, J.; Chiorini, J.A. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 2001, 75, 6884–6893.
  60. Kaludov, N.; Handelman, B.; Chiorini, J.A. Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum. Gene Ther. 2002, 13, 1235–1243.
  61. Bantel-Schaal, U.; zur Hausen, H. Characterization of the DNA of a defective human parvovirus isolated from a genital site. Virology 1984, 134, 52–63.
  62. Stutika, C.; Hüser, D.; Weger, S.; Rutz, N.; Heßler, M.; Heilbronn, R. Definition of herpes simplex virus helper functions for the replication of adeno-associated virus type 5. J. Gen. Virol. 2015, 96, 840–850.
  63. Bantel-Schaal, U.; Delius, H.; Schmidt, R.; Hausen, H.Z. Human Adeno-Associated Virus Type 5 Is Only Distantly Related to Other Known Primate Helper-Dependent Parvoviruses. J. Virol. 1999, 73, 939–947.
  64. Chiorini, J.A.; Kim, F.; Yang, L.; Kotin, R.M. Cloning and characterization of adeno-associated virus type 5. J. Virol. 1999, 73, 1309–1319.
  65. Bantel-Schaal, U.; Hub, B.; Kartenbeck, J. Endocytosis of adeno-associated virus type 5 leads to accumulation of virus particles in the Golgi compartment. J. Virol. 2002, 76, 2340–2349.
  66. Zabner, J.; Seiler, M.; Walters, R.; Kotin, R.M.; Fulgeras, W.; Davidson, B.L.; Chiorini, J.A. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J. Virol. 2000, 74, 3852–3858.
  67. Grimm, D.; Kay, M.A. From virus evolution to vector revolution: Use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther. 2003, 3, 281–304.
  68. Walters, R.W.; Yi, S.M.; Keshavjee, S.; Brown, K.E.; Welsh, M.J.; Chiorini, J.A.; Zabner, J. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J. Biol. Chem. 2001, 276, 20610–20616.
  69. Henckaerts, E.; Linden, R.M. Adeno-associated virus: A key to the human genome? Future Virol. 2010, 5, 555–574.
  70. Di Pasquale, G.; Davidson, B.L.; Stein, C.S.; Martins, I.; Scudiero, D.; Monks, A.; Chiorini, J.A. Identification of PDGFR as a receptor for AAV-5 transduction. Nat. Med. 2003, 9, 1306–1312.
  71. Nonnenmacher, M.; Weber, T. Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther. 2012, 19, 649–658.
  72. Xiao, W.; Chirmule, N.; Berta, S.C.; McCullough, B.; Gao, G.; Wilson, J.M. Gene Therapy Vectors Based on Adeno-Associated Virus Type 1. J. Virol. 1999, 73, 3994–4003.
  73. Rutledge, E.A.; Halbert, C.L.; Russell, D.W. Infectious Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2. J. Virol. 1998, 72, 309–319.
  74. Korneyenkov, M.A.; Zamyatnin, A.A., Jr. Next Step in Gene Delivery: Modern Approaches and Further Perspectives of AAV Tropism Modification. Pharmaceutics 2021, 13, 750.
  75. Ng, R.; Govindasamy, L.; Gurda, B.L.; McKenna, R.; Kozyreva, O.G.; Samulski, R.J.; Parent, K.N.; Baker, T.S.; Agbandje-McKenna, M. Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J. Virol. 2010, 84, 12945–12957.
  76. Wu, Z.; Asokan, A.; Grieger, J.C.; Govindasamy, L.; Agbandje-McKenna, M.; Samulski, R.J. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J. Virol. 2006, 80, 11393–11397.
  77. Weller, M.L.; Amornphimoltham, P.; Schmidt, M.; Wilson, P.A.; Gutkind, J.S.; Chiorini, J.A. Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat. Med. 2010, 16, 662–664.
  78. Gao, G.; Vandenberghe, L.H.; Alvira, M.R.; Lu, Y.; Calcedo, R.; Zhou, X.; Wilson, J.M. Clades of Adeno-associated viruses are widely disseminated in human tissues. J. Virol. 2004, 78, 6381–6388.
  79. Denby, L.; Nicklin, S.A.; Baker, A.H. Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation. Gene Ther. 2005, 12, 1534–1538.
  80. Mietzsch, M.; Broecker, F.; Reinhardt, A.; Seeberger, P.H.; Heilbronn, R. Differential Adeno-Associated Virus Serotype-Specific Interaction Patterns with Synthetic Heparins and Other Glycans. J. Virol. 2014, 88, 2991–3003.
  81. Calcedo, R.; Vandenberghe, L.H.; Gao, G.; Lin, J.; Wilson, J.M. Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses. J. Infect. Dis. 2009, 199, 381–390.
  82. Louboutin, J.-P.; Wang, L.; Wilson, J.M. Gene transfer into skeletal muscle using novel AAV serotypes. J. Gene Med. A Cross-Discip. J. Res. Sci. Gene Transf. Clin. Appl. 2005, 7, 442–451.
  83. Zincarelli, C.; Soltys, S.; Rengo, G.; Rabinowitz, J.E. Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 2008, 16, 1073–1080.
  84. Samaranch, L.; Salegio, E.A.; San Sebastian, W.; Kells, A.P.; Bringas, J.R.; Forsayeth, J.; Bankiewicz, K.S. Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum. Gene Ther. 2013, 24, 526–532.
  85. Okada, T.; Nonaka-Sarukawa, M.; Uchibori, R.; Kinoshita, K.; Hayashita-Kinoh, H.; Nitahara-Kasahara, Y.; Takeda, S.i.; Ozawa, K. Scalable purification of adeno-associated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes. Hum. Gene Ther. 2009, 20, 1013–1021.
  86. Davidoff, A.M.; Ng, C.Y.; Sleep, S.; Gray, J.; Azam, S.; Zhao, Y.; McIntosh, J.H.; Karimipoor, M.; Nathwani, A.C. Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J. Virol. Methods 2004, 121, 209–215.
  87. Lane, M.D.; Nam, H.-J.; Padron, E.; Gurda-Whitaker, B.; Kohlbrenner, E.; Aslanidi, G.; Byrne, B.; McKenna, R.; Muzyczka, N.; Zolotukhin, S.; et al. Production, purification, crystallization and preliminary X-ray analysis of adeno-associated virus serotype 8. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2005, 61, 558–561.
  88. Miyake, K.; Miyake, N.; Yamazaki, Y.; Shimada, T.; Hirai, Y.J. Serotype-independent method of recombinant adeno-associated virus (AAV) vector production and purification. J. Nippon. Med. Sch. 2012, 79, 394–402.
  89. Pañeda, A.; Vanrell, L.; Mauleon, I.; Crettaz, J.S.; Berraondo, P.; Timmermans, E.J.; Beattie, S.G.; Twisk, J.; van Deventer, S.; Prieto, J.; et al. Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders. Hum. Gene Ther. 2009, 20, 908–917.
  90. Nam, H.-J.; Lane, M.D.; Padron, E.; Gurda, B.; McKenna, R.; Kohlbrenner, E.; Aslanidi, G.; Byrne, B.; Muzyczka, N.; Zolotukhin, S.; et al. Structure of Adeno-Associated Virus Serotype 8, a Gene Therapy Vector. J. Virol. 2007, 81, 12260–12271.
  91. Cabanes-Creus, M.; Navarro, R.G.; Zhu, E.; Baltazar, G.; Liao, S.H.Y.; Drouyer, M.; Amaya, A.K.; Scott, S.; Nguyen, L.H.; Westhaus, A.; et al. Novel human liver-tropic AAV variants define transferable domains that markedly enhance the human tropism of AAV7 and AAV8. Mol. Ther. Methods Clin. Dev. 2022, 24, 88–101.
  92. Nakai, H.; Fuess, S.; Storm, T.A.; Muramatsu, S.; Nara, Y.; Kay, M.A. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J. Virol. 2005, 79, 214–224.
  93. Thomas, C.E.; Storm, T.A.; Huang, Z.; Kay, M.A. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol. 2004, 78, 3110–3122.
  94. Nam, H.-J.; Gurda, B.L.; McKenna, R.; Potter, M.; Byrne, B.; Salganik, M.; Muzyczka, N.; Agbandje-McKenna, M. Structural Studies of Adeno-Associated Virus Serotype 8 Capsid Transitions Associated with Endosomal Trafficking. J. Virol. 2011, 85, 11791–11799.
  95. Monahan, P.E.; Lothrop, C.D.; Sun, J.; Hirsch, M.L.; Kafri, T.; Kantor, B.; Sarkar, R.; Tillson, D.M.; Elia, J.R.; Samulski, R.J. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: A strategy for broad clinical application. Mol. Ther. J. Am. Soc. Gene Ther. 2010, 18, 1907–1916.
  96. Jiang, H.; Couto, L.B.; Patarroyo-White, S.; Liu, T.; Nagy, D.; Vargas, J.A.; Zhou, S.; Scallan, C.D.; Sommer, J.; Vijay, S.; et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 2006, 108, 3321–3328.
  97. Gao, G.; Vandenberghe, L.H.; Wilson, J.M. New recombinant serotypes of AAV vectors. Curr. Gene Ther. 2005, 5, 285–297.
  98. Shen, S.; Bryant, K.D.; Brown, S.M.; Randell, S.H.; Asokan, A. Terminal N-Linked Galactose Is the Primary Receptor for Adeno-associated Virus 9*. J. Biol. Chem. 2011, 286, 13532–13540.
  99. Bell, C.L.; Gurda, B.L.; Van Vliet, K.; Agbandje-McKenna, M.; Wilson, J.M. Identification of the galactose binding domain of the adeno- associated virus serotype 9 capsid. J. Virol. 2012, 86, 7326–7333.
  100. Mitchell, M.; Nam, H.-J.; Carter, A.; McCall, A.; Rence, C.; Bennett, A.; Gurda, B.; McKenna, R.; Porter, M.; Sakai, Y.; et al. Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 9. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2009, 65, 715–718.
  101. Vance, M.A.; Mitchell, A.; Samulski, R.J. AAV Biology, Infectivity and Therapeutic Use from Bench to Clinic. In Gene Therapy—Principles and Challenges; IntechOpen: London, UK, 2015.
  102. Vandenberghe, L.H.; Miller, J.R.; Gao, G.-P.; Calcedo, R.; Wilson, J.M. 116. The Proposed AAV Serotypes 10 and 11 Serologically Cross-React with AAV8 and AAV4. Mol. Ther. 2006, 13, S47.
  103. Klein, R.L.; Dayton, R.D.; Tatom, J.B.; Henderson, K.M.; Henning, P.P. AAV8, 9, Rh10, Rh43 Vector Gene Transfer in the Rat Brain: Effects of Serotype, Promoter and Purification Method. Mol. Ther. 2008, 16, 89–96.
  104. Schmidt, M.; Voutetakis, A.; Afione, S.; Zheng, C.; Mandikian, D.; Chiorini, J.A. Adeno-Associated Virus Type 12 (AAV12): A Novel AAV Serotype with Sialic Acid- and Heparan Sulfate Proteoglycan-Independent Transduction Activity. J. Virol. 2008, 82, 1399–1406.
  105. Schmidt, M.; Voutetakis, A.; Afione, S.; Zheng, C.; Chiorini, J.A. 745. AAV12, Isolated from Vervet Monkey, Has Unique Tropism and Biological as Well as Neutralization Properties. Mol. Ther. 2006, 13, S288.
  106. Schmidt, M.; Govindasamy, L.; Afione, S.; Kaludov, N.; Agbandje-McKenna, M.; Chiorini, J.A. Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 2008, 82, 8911–8916.
  107. Huang, L.-Y.; Halder, S.; Agbandje-McKenna, M. Parvovirus glycan interactions. Curr. Opin. Virol. 2014, 7, 108–118.
  108. Srivastava, A.J.C.; Insights, G.T. Advances and challenges in the use of recombinant AAV vectors for human gene therapy. Cell Gene Ther. Insights 2016, 2, 553–575.
  109. Mietzsch, M.; Jose, A.; Chipman, P.; Bhattacharya, N.; Daneshparvar, N.; McKenna, R.; Agbandje-McKenna, M. Completion of the AAV Structural Atlas: Serotype Capsid Structures Reveals Clade-Specific Features. Viruses 2021, 13, 101.
  110. Muzyczka, N.; Warrington, K.H., Jr. Custom adeno-associated virus capsids: The next generation of recombinant vectors with novel tropism. Hum. Gene Ther. 2005, 16, 408–416.
  111. Zhang, L.; Rossi, A.; Lange, L.; Meumann, N.; Koitzsch, U.; Christie, K.; Nesbit, M.A.; Moore, C.B.T.; Hacker, U.T.; Morgan, M.; et al. Capsid Engineering Overcomes Barriers Toward Adeno-Associated Virus Vector-Mediated Transduction of Endothelial Cells. Hum. Gene Ther. 2019, 30, 1284–1296.
  112. Ward, P.; Walsh, C.E. Chimeric AAV Cap sequences alter gene transduction. Virology 2009, 386, 237–248.
  113. Yang, L.; Jiang, J.; Drouin, L.M.; Agbandje-McKenna, M.; Chen, C.; Qiao, C.; Pu, D.; Hu, X.; Wang, D.Z.; Li, J.; et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc. Natl. Acad. Sci. USA 2009, 106, 3946–3951.
  114. White, A.F.; Mazur, M.; Sorscher, E.J.; Zinn, K.R.; Ponnazhagan, S. Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells. Hum. Gene Ther. 2008, 19, 1407–1414.
  115. Zhang, C.; Freistaedter, A.; Schmelas, C.; Gunkel, M.; Dao Thi, V.L.; Grimm, D. An RNA Interference/Adeno-Associated Virus Vector-Based Combinatorial Gene Therapy Approach Against Hepatitis E Virus. Hepatol. Commun. 2022, 6, 878–888.
  116. Van Vliet, K.M.; Blouin, V.; Brument, N.; Agbandje-McKenna, M.; Snyder, R.O. The role of the adeno-associated virus capsid in gene transfer. Methods Mol. Biol. 2008, 437, 51–91.
  117. McCown, T.J. Adeno-associated virus (AAV) vectors in the CNS. Curr. Gene Ther. 2005, 5, 333–338.
  118. Gray, S.J.; Matagne, V.; Bachaboina, L.; Yadav, S.; Ojeda, S.R.; Samulski, R.J. Preclinical Differences of Intravascular AAV9 Delivery to Neurons and Glia: A Comparative Study of Adult Mice and Nonhuman Primates. Mol. Ther. 2011, 19, 1058–1069.
  119. Gray, S.J.; Nagabhushan Kalburgi, S.; McCown, T.J.; Jude Samulski, R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 2013, 20, 450–459.
  120. Kaplitt, M.G.; Leone, P.; Samulski, R.J.; Xiao, X.; Pfaff, D.W.; O’Malley, K.L.; During, M.J. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 1994, 8, 148–154.
  121. McElroy, A.; Sena-Esteves, M.; Arjomandnejad, M.; Keeler, A.M.; Gray-Edwards, H.L. Redosing Adeno-Associated Virus Gene Therapy to the Central Nervous System. Hum. Gene Ther. 2022, 33, 889–892.
  122. Bartus, R.T.; Weinberg, M.S.; Samulski, R.J. Parkinson’s Disease Gene Therapy: Success by Design Meets Failure by Efficacy. Mol. Ther. 2014, 22, 487–497.
  123. Marks, W.J.; Bartus, R.T.; Siffert, J.; Davis, C.S.; Lozano, A.; Boulis, N.; Vitek, J.; Stacy, M.; Turner, D.; Verhagen, L.; et al. Gene delivery of AAV2-neurturin for Parkinson’s disease: A double-blind, randomised, controlled trial. Lancet Neurol. 2010, 9, 1164–1172.
  124. Kaplitt, M.G.; Feigin, A.; Tang, C.; Fitzsimons, H.L.; Mattis, P.; Lawlor, P.A.; Bland, R.J.; Young, D.; Strybing, K.; Eidelberg, D.; et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: An open label, phase I trial. Lancet 2007, 369, 2097–2105.
  125. LeWitt, P.A.; Rezai, A.R.; Leehey, M.A.; Ojemann, S.G.; Flaherty, A.W.; Eskandar, E.N.; Kostyk, S.K.; Thomas, K.; Sarkar, A.; Siddiqui, M.S.; et al. AAV2-GAD gene therapy for advanced Parkinson’s disease: A double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011, 10, 309–319.
  126. Bartus, R.T.; Baumann, T.L.; Siffert, J.; Herzog, C.D.; Alterman, R.; Boulis, N.; Turner, D.A.; Stacy, M.; Lang, A.E.; Lozano, A.M.; et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 2013, 80, 1698–1701.
  127. Christine, C.W.; Starr, P.A.; Larson, P.S.; Eberling, J.L.; Jagust, W.J.; Hawkins, R.A.; VanBrocklin, H.F.; Wright, J.F.; Bankiewicz, K.S.; Aminoff, M.J. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009, 73, 1662–1669.
  128. Mittermeyer, G.; Christine, C.W.; Rosenbluth, K.H.; Baker, S.L.; Starr, P.; Larson, P.; Kaplan, P.L.; Forsayeth, J.; Aminoff, M.J.; Bankiewicz, K.S. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson’s disease. Hum. Gene Ther. 2012, 23, 377–381.
  129. Chien, Y.H.; Lee, N.C.; Tseng, S.H.; Tai, C.H.; Muramatsu, S.I.; Byrne, B.J.; Hwu, W.L. Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: An open-label, phase 1/2 trial. Lancet Child Adolesc. Health 2017, 1, 265–273.
  130. Sondhi, D.; Stiles, K.M.; De, B.P.; Crystal, R.G. Genetic Modification of the Lung Directed Toward Treatment of Human Disease. Hum. Gene Ther. 2017, 28, 3–84.
  131. McLachlan, G.; Alton, E.; Boyd, A.C.; Clarke, N.K.; Davies, J.C.; Gill, D.R.; Griesenbach, U.; Hickmott, J.W.; Hyde, S.C.; Miah, K.M.; et al. Progress in Respiratory Gene Therapy. Hum. Gene Ther. 2022, 33, 893–912.
  132. Burney, T.J.; Davies, J.C. Gene therapy for the treatment of cystic fibrosis. Appl. Clin. Genet. 2012, 5, 29.
  133. Flotte, T.R.; Afione, S.A.; Conrad, C.; McGrath, S.A.; Solow, R.; Oka, H.; Zeitlin, P.L.; Guggino, W.B.; Carter, B.J. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc. Natl. Acad. Sci. USA 1993, 90, 10613–10617.
  134. Guggino, W.B.; Cebotaru, L. Gene therapy for cystic fibrosis paved the way for the use of adeno-associated virus in gene therapy. Hum. Gene Ther. 2020, 31, 538–541.
  135. Wagner, J.A.; Reynolds, T.; Moran, M.L.; Moss, R.B.; Wine, J.J.; Flotte, T.R.; Gardner, P. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet 1998, 351, 1702–1703.
  136. Wagner, J.A.; Nepomuceno, I.B.; Messner, A.H.; Moran, M.L.; Batson, E.P.; Dimiceli, S.; Brown, B.W.; Desch, J.K.; Norbash, A.M.; Conrad, C.K. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum. Gene Ther. 2002, 13, 1349–1359.
  137. Aitken, M.; Moss, R.; Waltz, D.; Dovey, M.; Tonelli, M.; McNamara, S.; Gibson, R.; Ramsey, B.; Carter, B.; Reynolds, T. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum. Gene Ther. 2001, 12, 1907–1916.
  138. Flotte, T.R.; Zeitlin, P.L.; Reynolds, T.C.; Heald, A.E.; Pedersen, P.; Beck, S.; Conrad, C.K.; Brass-Ernst, L.; Humphries, M.; Sullivan, K. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: A two-part clinical study. Hum. Gene Ther. 2003, 14, 1079–1088.
  139. Moss, R.B.; Rodman, D.; Spencer, L.T.; Aitken, M.L.; Zeitlin, P.L.; Waltz, D.; Milla, C.; Brody, A.S.; Clancy, J.P.; Ramsey, B. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: A multicenter, double-blind, placebo-controlled trial. Chest 2004, 125, 509–521.
  140. Moss, R.B.; Milla, C.; Colombo, J.; Accurso, F.; Zeitlin, P.L.; Clancy, J.P.; Spencer, L.T.; Pilewski, J.; Waltz, D.A.; Dorkin, H.L. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: A randomized placebo-controlled phase 2B trial. Hum. Gene Ther. 2007, 18, 726–732.
  141. Kurosaki, F.; Uchibori, R.; Mato, N.; Sehara, Y.; Saga, Y.; Urabe, M.; Mizukami, H.; Sugiyama, Y.; Kume, A. Optimization of adeno-associated virus vector-mediated gene transfer to the respiratory tract. Gene Ther. 2017, 24, 290–297.
  142. Cooney, A.L.; McCray, P.B.; Sinn, P.L. Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward. Genes 2018, 9, 538.
  143. Stiles, K.M.; Sondhi, D.; Kaminsky, S.M.; De, B.P.; Rosenberg, J.B.; Crystal, R.G. Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency-Related Lung Disease. Chronic Obstr. Pulm. Dis. 2018, 5, 244–257.
  144. Song, S.; Embury, J.; Laipis, P.; Berns, K.; Crawford, J.; Flotte, T. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 2001, 8, 1299–1306.
  145. Conlon, T.J.; Cossette, T.; Erger, K.; Choi, Y.-K.; Clarke, T.; Scott-Jorgensen, M.; Song, S.; Campbell-Thompson, M.; Crawford, J.; Flotte, T.R. Efficient Hepatic Delivery and Expression from a Recombinant Adeno-associated Virus 8 Pseudotyped α1-Antitrypsin Vector. Mol. Ther. 2005, 12, 867–875.
  146. De, B.; Heguy, A.; Leopold, P.L.; Wasif, N.; Korst, R.J.; Hackett, N.R.; Crystal, R.G. Intrapleural administration of a serotype 5 adeno-associated virus coding for α1-antitrypsin mediates persistent, high lung and serum levels of α1-antitrypsin. Mol. Ther. 2004, 10, 1003–1010.
  147. Chulay, J.D.; Ye, G.J.; Thomas, D.L.; Knop, D.R.; Benson, J.M.; Hutt, J.A.; Wang, G.; Humphries, M.; Flotte, T.R. Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method. Hum. Gene Ther. 2011, 22, 155–165.
  148. Limberis, M.P.; Vandenberghe, L.H.; Zhang, L.; Pickles, R.J.; Wilson, J.M. Transduction Efficiencies of Novel AAV Vectors in Mouse Airway Epithelium In Vivo and Human Ciliated Airway Epithelium In Vitro. Mol. Ther. 2009, 17, 294–301.
  149. Guse, K.; Suzuki, M.; Sule, G.; Bertin, T.K.; Tyynismaa, H.; Ahola-Erkkilä, S.; Palmer, D.; Suomalainen, A.; Ng, P.; Cerullo, V.; et al. Capsid-modified adenoviral vectors for improved muscle-directed gene therapy. Hum. Gene Ther. 2012, 23, 1065–1070.
  150. Tang, Y.; Cummins, J.; Huard, J.; Wang, B. AAV-directed muscular dystrophy gene therapy. Expert Opin. Biol. Ther. 2010, 10, 395–408.
  151. Kota, J.; Handy, C.R.; Haidet, A.M.; Montgomery, C.L.; Eagle, A.; Rodino-Klapac, L.R.; Tucker, D.; Shilling, C.J.; Therlfall, W.R.; Walker, C.M.; et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci. Transl. Med. 2009, 1, 6ra15.
  152. Gregorevic, P.; Allen, J.M.; Minami, E.; Blankinship, M.J.; Haraguchi, M.; Meuse, L.; Finn, E.; Adams, M.E.; Froehner, S.C.; Murry, C.E.; et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med. 2006, 12, 787–789.
  153. Wang, B.; Li, J.; Fu, F.H.; Xiao, X. Systemic human minidystrophin gene transfer improves functions and life span of dystrophin and dystrophin/utrophin-deficient mice. J. Orthop. Res. Off. Publ. Orthop. Res. Soc. 2009, 27, 421–426.
  154. Zhu, T.; Zhou, L.; Mori, S.; Wang, Z.; McTiernan, C.F.; Qiao, C.; Chen, C.; Wang, D.W.; Li, J.; Xiao, X. Sustained Whole-Body Functional Rescue in Congestive Heart Failure and Muscular Dystrophy Hamsters by Systemic Gene Transfer. Circulation 2005, 112, 2650–2659.
  155. Pacak, C.A.; Walter, G.A.; Gaidosh, G.; Bryant, N.; Lewis, M.A.; Germain, S.; Mah, C.S.; Campbell, K.P.; Byrne, B.J. Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D. Mol. Ther. J. Am. Soc. Gene Ther. 2007, 15, 1775–1781.
  156. Fougerousse, F.; Bartoli, M.; Poupiot, J.; Arandel, L.; Durand, M.; Guerchet, N.; Gicquel, E.; Danos, O.; Richard, I. Phenotypic Correction of α-Sarcoglycan Deficiency by Intra-arterial Injection of a Muscle-specific Serotype 1 rAAV Vector. Mol. Ther. J. Am. Soc. Gene Ther. 2007, 15, 53–61.
  157. Cordier, L.; Hack, A.A.; Scott, M.O.; Barton-Davis, E.R.; Gao, G.; Wilson, J.M.; McNally, E.M.; Sweeney, H.L. Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer. Mol. Ther. J. Am. Soc. Gene Ther. 2000, 1, 119–129.
  158. Bartoli, M.; Roudaut, C.; Martin, S.; Fougerousse, F.; Suel, L.; Poupiot, J.; Gicquel, E.; Noulet, F.; Danos, O.; Richard, I. Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A. Mol. Ther. J. Am. Soc. Gene Ther. 2006, 13, 250–259.
  159. White, J.D.; Thesier, D.M.; Swain, J.B.; Katz, M.G.; Tomasulo, C.; Henderson, A.; Wang, L.; Yarnall, C.; Fargnoli, A.; Sumaroka, M.; et al. Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo. Gene Ther. 2011, 18, 546–552.
  160. World Health Organization. Cardiovascular Diseases (CVDs). Available online: https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (accessed on 1 December 2022).
  161. Raake, P.W.; Hinkel, R.; Müller, S.; Delker, S.; Kreuzpointner, R.; Kupatt, C.; Katus, H.A.; Kleinschmidt, J.A.; Boekstegers, P.; Müller, O.J. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors. Gene Ther. 2008, 15, 12–17.
  162. Bish, L.T.; Morine, K.; Sleeper, M.M.; Sanmiguel, J.; Wu, D.; Gao, G.; Wilson, J.M.; Sweeney, H.L. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum. Gene Ther. 2008, 19, 1359–1368.
  163. Vandendriessche, T.; Thorrez, L.; Acosta-Sanchez, A.; Petrus, I.; Wang, L.; Ma, L.; De Waele, L.; Iwasaki, Y.; Gillijns, V.; Wilson, J.M.; et al. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J. Thromb. Haemost. JTH 2007, 5, 16–24.
  164. Jiang, H.; Lillicrap, D.; Patarroyo-White, S.; Liu, T.; Qian, X.; Scallan, C.D.; Powell, S.; Keller, T.; McMurray, M.; Labelle, A.; et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 2006, 108, 107–115.
  165. Zsebo, K.; Yaroshinsky, A.; Rudy, J.J.; Wagner, K.; Greenberg, B.; Jessup, M.; Hajjar, R.J. Long-Term Effects of AAV1/SERCA2a Gene Transfer in Patients With Severe Heart Failure. Circ. Res. 2014, 114, 101–108.
  166. Nguyen, T.H.; Ferry, N. Liver gene therapy: Advances and hurdles. Gene Ther. 2004, 11, S76–S84.
  167. Członkowska, A.; Litwin, T.; Dusek, P.; Ferenci, P.; Lutsenko, S.; Medici, V.; Rybakowski, J.K.; Weiss, K.H.; Schilsky, M.L. Wilson disease. Nat. Rev. Dis. Prim. 2018, 4, 21.
  168. Murillo, O.; Collantes, M.; Gazquez, C.; Moreno, D.; Hernandez-Alcoceba, R.; Barberia, M.; Ecay, M.; Tamarit, B.; Douar, A.; Ferrer, V.; et al. High value of (64)Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson’s disease. Mol. Ther. Methods Clin. Dev. 2022, 26, 98–106.
  169. Murillo, O.; Moreno, D.; Gazquez, C.; Barberia, M.; Cenzano, I.; Navarro, I.; Uriarte, I.; Sebastian, V.; Arruebo, M.; Ferrer, V.; et al. Liver Expression of a MiniATP7B Gene Results in Long-Term Restoration of Copper Homeostasis in a Wilson Disease Model in Mice. Hepatology 2019, 70, 108–126.
  170. Golden, S.H.; Robinson, K.A.; Saldanha, I.; Anton, B.; Ladenson, P.W. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: A comprehensive review. J. Clin. Endocrinol. Metab. 2009, 94, 1853–1878.
  171. Wilson, J.D. Prospects for research for disorders of the endocrine system. JAMA 2001, 285, 624–627.
  172. Barzon, L.; Bonaguro, R.; Palù, G.; Boscaro, M. New perspectives for gene therapy in endocrinology. Eur. J. Endocrinol. 2000, 143, 447–466.
  173. Chellappan, D.K.; Sivam, N.S.; Teoh, K.X.; Leong, W.P.; Fui, T.Z.; Chooi, K.; Khoo, N.; Yi, F.J.; Chellian, J.; Cheng, L.L.; et al. Gene therapy and type 1 diabetes mellitus. Biomed. Pharmacother. 2018, 108, 1188–1200.
  174. Atkinson, M.A. Chapter 32—Type 1 Diabetes Mellitus. In Williams Textbook of Endocrinology, 3rd ed.; Melmed, S., Polonsky, K.S., Larsen, P.R., Kronenberg, H.M., Eds.; Elsevier: Philadelphia, PA, USA, 2016; pp. 1451–1483.
  175. Flores, R.R.; Zhou, L.; Robbins, P.D. Expression of IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabetes through activation of FoxP3-positive regulatory T cells. Gene Ther. 2014, 21, 715–722.
  176. Zhang, Y.C.; Pileggi, A.; Agarwal, A.; Molano, R.D.; Powers, M.; Brusko, T.; Wasserfall, C.; Goudy, K.; Zahr, E.; Poggioli, R.; et al. Adeno-Associated Virus-Mediated IL-10 Gene Therapy Inhibits Diabetes Recurrence in Syngeneic Islet Cell Transplantation of NOD Mice. Diabetes 2003, 52, 708–716.
  177. El Khatib, M.; Sakuma, T.; Tonne, J.M.; Mohamed, M.S.; Holditch, S.J.; Lu, B.; Kudva, Y.C.; Ikeda, Y. β-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection. Gene Ther. 2015, 22, 430–438.
  178. Luo, J.; Luo, Y.; Sun, J.; Zhou, Y.; Zhang, Y.; Yang, X. Adeno-associated virus-mediated cancer gene therapy: Current status. Cancer Lett. 2015, 356, 347–356.
  179. WHO. Cancer. Available online: https://www.who.int/news-room/fact-sheets/detail/cancer (accessed on 1 December 2022).
  180. Kanazawa, T.; Mizukami, H.; Okada, T.; Hanazono, Y.; Kume, A.; Nishino, H.; Takeuchi, K.; Kitamura, K.; Ichimura, K.; Ozawa, K. Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther. 2003, 10, 51–58.
  181. Kim, J.Y.; Kim, J.H.; Khim, M.; Lee, H.S.; Jung, J.H.; Moon, D.H.; Jeong, S.; Lee, H. Persistent anti-tumor effects via recombinant adeno-associated virus encoding herpes thymidine kinase gene monitored by PET-imaging. Oncol. Rep. 2011, 25, 1263–1269.
  182. Mizuno, M.; Yoshida, J.; Colosi, P.; Kurtzman, G. Adeno-associated Virus Vector Containing the Herpes Simplex Virus Thymidine Kinase Gene Causes Complete Regression of Intracerebrally Implanted Human Gliomas in Mice, in Conjunction with Ganciclovir Administration. Jpn. J. Cancer Res. 1998, 89, 76–80.
  183. Kojima, Y.; Honda, K.; Hamada, H.; Kobayashi, N. Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models. J. Surg. Res. 2009, 157, e63–e70.
  184. Pan, J.G.; Zhou, X.; Luo, R.; Han, R.F. The adeno-associated virus-mediated HSV-TK/GCV suicide system: A potential strategy for the treatment of bladder carcinoma. Med. Oncol. 2012, 29, 1938–1947.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Biochemistry & Molecular Biology; Virology; Medicine, Research & Experimental
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Shaza Saleh Issa
,
Alisa A. Shaimardanova
,
Valeriya Solovyeva
,
Albert A. Rizvanov
View Times: 202
Revisions: 2 times (View History)
Update Date: 06 May 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback